These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16460494)

  • 1. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis.
    Kee KM; Lee CM; Wang JH; Tung HD; Changchien CS; Lu SN; Wang PW
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):319-26. PubMed ID: 16460494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C.
    Hwang Y; Kim W; Kwon SY; Yu HM; Kim JH; Choe WH
    Korean J Intern Med; 2015 Nov; 30(6):792-800. PubMed ID: 26552454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient Hypothyroidism and Autoimmune Thyroiditis in Children With Chronic Hepatitis C Treated With Pegylated-interferon-α-2b and Ribavirin.
    Serranti D; Indolfi G; Nebbia G; Cananzi M; D'Antiga L; Ricci S; Stagi S; Azzari C; Resti M;
    Pediatr Infect Dis J; 2018 Apr; 37(4):287-291. PubMed ID: 28953189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of combined interferon alpha and ribavirin therapy on thyroid functions in patients with chronic hepatitis C.
    Nadeem A; Aslam M; Khan DA; Hussain T; Khan SA
    J Coll Physicians Surg Pak; 2009 Feb; 19(2):86-9. PubMed ID: 19208310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
    Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J
    J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan.
    Chang YK; Tseng YT; Chen KH; Chen KT
    BMC Endocr Disord; 2019 Apr; 19(1):36. PubMed ID: 30953492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism.
    Carella C; Mazziotti G; Morisco F; Rotondi M; Cioffi M; Tuccillo C; Sorvillo F; Caporaso N; Amato G
    Eur J Endocrinol; 2002 Jun; 146(6):743-9. PubMed ID: 12039693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of thyroid dysfunction and influencing factors in chronic hepatitis C patients treated with peg-IFNa-2a and ribavirin].
    Huang YX; Chen XY; Ma LN; Yin JM; Ren S; Guo DD; Zheng YH
    Zhonghua Gan Zang Bing Za Zhi; 2012 Mar; 20(3):216-20. PubMed ID: 22475143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study.
    Bini EJ; Mehandru S
    Arch Intern Med; 2004 Nov; 164(21):2371-6. PubMed ID: 15557418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy.
    Huang JF; Chuang WL; Dai CY; Chen SC; Lin ZY; Lee LP; Lee PL; Wang LY; Hsieh MY; Chang WY; Yu ML
    J Viral Hepat; 2006 Jun; 13(6):396-401. PubMed ID: 16842442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010.
    Barut S; Gunal O; Erkorkmaz U; Yildiz F
    Braz J Infect Dis; 2012; 16(5):448-51. PubMed ID: 22964290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related?
    Vezali E; Elefsiniotis I; Mihas C; Konstantinou E; Saroglou G
    J Gastroenterol Hepatol; 2009 Jun; 24(6):1024-9. PubMed ID: 19383078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypes of interferon-α-induced thyroid dysfunction among patients treated for hepatitis C are associated with pretreatment serum TSH and female sex.
    Mammen JS; Ghazarian SR; Pulkstenis E; Subramanian GM; Rosen A; Ladenson PW
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3270-6. PubMed ID: 22689690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Thyroid dysfunctions in children with chronic hepatitis C during interferon alpha-2b therapy].
    Kupś-Rzepecka J; Woźniakowska-Gesicka T; Gołabek V
    Przegl Lek; 2011; 68(6):311-5. PubMed ID: 22039668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid dysfunction in a UK hepatitis C population treated with interferon-alpha and ribavirin combination therapy.
    Costelloe SJ; Wassef N; Schulz J; Vaghijiani T; Morris C; Whiting S; Thomas M; Dusheiko G; Jacobs M; Vanderpump MP
    Clin Endocrinol (Oxf); 2010 Aug; 73(2):249-56. PubMed ID: 20148905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical observation of Hashimoto thyroiditis in patients with chronic hepatitis C undergoing pegylated-interferon alpha-2a and ribavirin combination therapy].
    Teng ZL; Gong WJ; Zhang SQ; Sun YX; Ma XH
    Zhonghua Gan Zang Bing Za Zhi; 2013 Feb; 21(2):101-4. PubMed ID: 23663880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
    Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
    J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-induced thyroid dysfunction in chronic hepatitis C.
    Jamil KM; Leedman PJ; Kontorinis N; Tarquinio L; Nazareth S; McInerney M; Connelly C; Flexman J; Burke V; Metcalf C; Cheng W
    J Gastroenterol Hepatol; 2009 Jun; 24(6):1017-23. PubMed ID: 19054259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virologic factors related to interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C.
    Hsieh MC; Yu ML; Chuang WL; Shin SJ; Dai CY; Chen SC; Lin ZY; Hsieh MY; Liu JF; Wang LY; Chang WY
    Eur J Endocrinol; 2000 May; 142(5):431-7. PubMed ID: 10802518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated interferon-alpha2beta in combination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon-alpha2beta in a hepatitis C population: meta-analysis.
    Tran HA; Attia JR; Jones TL; Batey RG
    J Gastroenterol Hepatol; 2007 Apr; 22(4):472-6. PubMed ID: 17376035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.